Genpharmasec Limited

As of June 30, 2026, Genpharmasec Limited carries a market capitalization of 609.09M, placing it among publicly traded companies globally. Its enterprise value stands at 609.09M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Genpharmasec Limited has 553.72M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Genpharmasec Limited trades at an EV/EBITDA multiple of 49.11 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.34 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 609.09M versus a market cap of 609.09M, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 154.44M in revenue per employee across its workforce of 11.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Genpharmasec Limited recorded 8.11M in income tax expense. The company reported a pretax loss of -177,000.00 and -5.55M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Genpharmasec Limited's stock has declined approximately 43.82% over the past 52 weeks. The 50-day moving average sits at 1.08, while the 200-day moving average is 1.14.

Over the twelve months ended June 30, 2026, Genpharmasec Limited generated 1.78B in revenue and converted that into -5.55M in net income, yielding earnings per share of -0.01. EBITDA reached 12.40M, while operating income came in at -13.36M.

Over the twelve months ended June 30, 2026, Genpharmasec Limited posted a gross margin of 7.54, reflecting its pricing power and cost economics. The operating margin of -0.75 and net profit margin of -0.31 provide insight into operational efficiency.

Genpharmasec Limited's most recent stock split took place on January 9, 2024 with a 523:871 split ratio.